Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma
Hepatology2007Vol. 46(4), pp. 1119–1130
Citations Over TimeTop 10% of 2007 papers
Yen‐Shen Lu, Yoko Kashida, Samuel K. Kulp, Yu-Chieh Wang, Dasheng Wang, Jui‐Hsiang Hung, Mónica Tang, Zhong-Zhe Lin, Te-Jung Chen, Ann‐Lii Cheng, Ching-Shih Chen
Abstract
OSU-HDAC42 is a potent, orally bioavailable inhibitor of HDAC with a broad spectrum of antitumor activity that includes targets regulating multiple aspects of cancer cell survival. These results suggest that OSU-HDAC42 has clinical value in therapeutic strategies for HCC.
Related Papers
- → Inhibition of Class IIb Histone Deacetylase Significantly Improves Cloning Efficiency in Mice1(2010)112 cited
- → The Crosstalk between Acetylation and Phosphorylation: Emerging New Roles for HDAC Inhibitors in the Heart(2018)60 cited
- → Recent progress in the development of assays suited for histone deacetylase inhibitor screening(2003)42 cited
- → Supplementary Figures 1-8 from Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737(2023)
- → Supplementary Figures 1-2 from Histone Deacetylase Inhibitor–Mediated Radiosensitization of Human Cancer Cells: Class Differences and the Potential Influence of p53(2023)